NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair. more
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| NGEN | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| NGEN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
NervGen Pharma Corp (NGEN) share price today is $5.76
Yes, Indians can buy shares of NervGen Pharma Corp (NGEN) on Vested. To buy
Yes, you can purchase fractional shares of NervGen Pharma Corp (NGEN) via the Vested app. You can start investing in NervGen Pharma Corp (NGEN) with a minimum investment of $1.
You can invest in shares of NervGen Pharma Corp (NGEN) via Vested in three simple steps:
The 52-week high price of NervGen Pharma Corp (NGEN) is $. The 52-week low price of NervGen Pharma Corp (NGEN) is $.
The price-to-earnings (P/E) ratio of NervGen Pharma Corp (NGEN) is
The price-to-book (P/B) ratio of NervGen Pharma Corp (NGEN) is 0.00
The dividend yield of NervGen Pharma Corp (NGEN) is 0.00%
The market capitalization of NervGen Pharma Corp (NGEN) is
The stock symbol (or ticker) of NervGen Pharma Corp is NGEN
Link copied
